Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

6.240 +0.180 (+2.97%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	77,466
Open	6.130
Bid (Size)	6.210 (400)
Ask (Size)	6.350 (100)
Prev. Close	6.060
Today's Range	6.090 - 6.250
52wk Range	4.440 - 11.52
Shares Outstanding	19,495,683
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

November 25, 2025

Event scheduled for Tuesday, December 2nd at 8:00 AM ET

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

November 04, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Performance

YTD	+15.8%	+15.8%
1 Month	-7.8%	-7.8%
3 Month	-4.9%	-4.9%
6 Month	-33.7%	-33.7%
1 Year	+23.8%	+23.8%

More News

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 27, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 16, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

September 25, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

September 04, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

August 11, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis (NVCT) Q2 Loss Widens 43% ↗

August 05, 2025

Via The Motley Fool

Discover the top movers in Thursday's pre-market session. ↗

July 31, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 31, 2025

Via Benzinga

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

July 31, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

July 08, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

June 20, 2025

Via News Direct

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?

May 05, 2025

Via News Direct

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

April 29, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

March 26, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

March 14, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

March 05, 2025

From Market News Alerts

Via Business Wire

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

March 04, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

February 27, 2025

From Market News Alerts

Via Business Wire

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

February 07, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

February 04, 2025

From Nuvectis Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

Frequently Asked Questions

Is Nuvectis Pharma, Inc. - Common Stock publicly traded?

Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.

What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?

Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?

The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market

What is the current price of Nuvectis Pharma, Inc. - Common Stock?

The current price of Nuvectis Pharma, Inc. - Common Stock is 6.240

When was Nuvectis Pharma, Inc. - Common Stock last traded?

The last trade of Nuvectis Pharma, Inc. - Common Stock was at 11/28/25 01:00 PM ET

What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?

The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 121.65M

How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?

Nuvectis Pharma, Inc. - Common Stock has 122M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.